Cargando…
High affinity zoledronate-based metal complex nanocrystals to potentially treat osteolytic metastases
Formation of several materials, denoted as bisphosphonate-based coordination complexes (BPCCs), resulted from the reaction between clinically employed bisphosphonate, zoledronate (ZOLE) and bioactive metals (M(2+) = Ca(2+), Mg(2+) and Zn(2+)). Six ZOLE-based BPCCs were synthesized using different va...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
RSC
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8978309/ https://www.ncbi.nlm.nih.gov/pubmed/35445197 http://dx.doi.org/10.1039/d1ma01127h |
_version_ | 1784680938614030336 |
---|---|
author | Quiñones Vélez, Gabriel Carmona-Sarabia, Lesly Rivera Raíces, Alondra A. Hu, Tony Peterson-Peguero, Esther A. López-Mejías, Vilmalí |
author_facet | Quiñones Vélez, Gabriel Carmona-Sarabia, Lesly Rivera Raíces, Alondra A. Hu, Tony Peterson-Peguero, Esther A. López-Mejías, Vilmalí |
author_sort | Quiñones Vélez, Gabriel |
collection | PubMed |
description | Formation of several materials, denoted as bisphosphonate-based coordination complexes (BPCCs), resulted from the reaction between clinically employed bisphosphonate, zoledronate (ZOLE) and bioactive metals (M(2+) = Ca(2+), Mg(2+) and Zn(2+)). Six ZOLE-based BPCCs were synthesized using different variables (M(2+) : ZOLE molar ratio, temperature, pH, and anion) and their structures were elucidated by single crystal X-ray diffraction (ZOLE–Ca forms I and II, ZOLE–Mg forms I and II, and ZOLE–Zn forms I and II). The dissolution of the ZOLE-based BPCCs was compared to that of ZOLE (Reclast®). Most of the ZOLE-based BPCCs (60–85%, in 18–24 h) present a lower dissolution and equilibrium solubility than ZOLE (∼100%, 30 min) in phosphate buffered saline (PBS), while a significantly higher dissolution is observed in acidic media (88% in 1 h). This suggests the ability to release the ZOLE content in a pH-dependent manner. Moreover, a phase inversion temperature (PIT)-nano-emulsion synthesis was performed, which demonstrated the ability to significantly decrease the crystal size of ZOLE–Ca form II from a micron-range (∼200 μm) to a nano-range (∼150 d nm), resulting in nano-Ca@ZOLE. Furthermore, low aggregation of nano-Ca@ZOLE in 10% fetal bovine serum (FBS) : PBS after 0, 24 and 48 h was demonstrated. Additionally, nano-Ca@ZOLE showed an ∼2.5x more binding to hydroxyapatite (HA, 36%) than ZOLE (15%) in 1 d. The cytotoxicity of nano-Ca@ZOLE against MDA-MB-231 (cancer cell model) and hFOB 1.19 (normal osteoblast-like cell model) cell lines was investigated. The results demonstrated significant cell growth inhibition for nano-Ca@ZOLE against MDA-MB-231, specifically at a low concentration of 3.8 μM (%RCL = 55 ± 1%, 72 h). Under the same conditions, the nanocrystals did not present cytotoxicity against hFOB 1.19 (%RCL = 100 ± 2%). These results evidence that nano-ZOLE-based BPCCs possess viable properties in terms of structure, dissolution, stability, binding, and cytotoxicity, which render them suitable for osteolytic metastasis therapy. |
format | Online Article Text |
id | pubmed-8978309 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | RSC |
record_format | MEDLINE/PubMed |
spelling | pubmed-89783092022-04-18 High affinity zoledronate-based metal complex nanocrystals to potentially treat osteolytic metastases Quiñones Vélez, Gabriel Carmona-Sarabia, Lesly Rivera Raíces, Alondra A. Hu, Tony Peterson-Peguero, Esther A. López-Mejías, Vilmalí Mater Adv Chemistry Formation of several materials, denoted as bisphosphonate-based coordination complexes (BPCCs), resulted from the reaction between clinically employed bisphosphonate, zoledronate (ZOLE) and bioactive metals (M(2+) = Ca(2+), Mg(2+) and Zn(2+)). Six ZOLE-based BPCCs were synthesized using different variables (M(2+) : ZOLE molar ratio, temperature, pH, and anion) and their structures were elucidated by single crystal X-ray diffraction (ZOLE–Ca forms I and II, ZOLE–Mg forms I and II, and ZOLE–Zn forms I and II). The dissolution of the ZOLE-based BPCCs was compared to that of ZOLE (Reclast®). Most of the ZOLE-based BPCCs (60–85%, in 18–24 h) present a lower dissolution and equilibrium solubility than ZOLE (∼100%, 30 min) in phosphate buffered saline (PBS), while a significantly higher dissolution is observed in acidic media (88% in 1 h). This suggests the ability to release the ZOLE content in a pH-dependent manner. Moreover, a phase inversion temperature (PIT)-nano-emulsion synthesis was performed, which demonstrated the ability to significantly decrease the crystal size of ZOLE–Ca form II from a micron-range (∼200 μm) to a nano-range (∼150 d nm), resulting in nano-Ca@ZOLE. Furthermore, low aggregation of nano-Ca@ZOLE in 10% fetal bovine serum (FBS) : PBS after 0, 24 and 48 h was demonstrated. Additionally, nano-Ca@ZOLE showed an ∼2.5x more binding to hydroxyapatite (HA, 36%) than ZOLE (15%) in 1 d. The cytotoxicity of nano-Ca@ZOLE against MDA-MB-231 (cancer cell model) and hFOB 1.19 (normal osteoblast-like cell model) cell lines was investigated. The results demonstrated significant cell growth inhibition for nano-Ca@ZOLE against MDA-MB-231, specifically at a low concentration of 3.8 μM (%RCL = 55 ± 1%, 72 h). Under the same conditions, the nanocrystals did not present cytotoxicity against hFOB 1.19 (%RCL = 100 ± 2%). These results evidence that nano-ZOLE-based BPCCs possess viable properties in terms of structure, dissolution, stability, binding, and cytotoxicity, which render them suitable for osteolytic metastasis therapy. RSC 2022-02-23 /pmc/articles/PMC8978309/ /pubmed/35445197 http://dx.doi.org/10.1039/d1ma01127h Text en This journal is © The Royal Society of Chemistry https://creativecommons.org/licenses/by-nc/3.0/ |
spellingShingle | Chemistry Quiñones Vélez, Gabriel Carmona-Sarabia, Lesly Rivera Raíces, Alondra A. Hu, Tony Peterson-Peguero, Esther A. López-Mejías, Vilmalí High affinity zoledronate-based metal complex nanocrystals to potentially treat osteolytic metastases |
title | High affinity zoledronate-based metal complex nanocrystals to potentially treat osteolytic metastases |
title_full | High affinity zoledronate-based metal complex nanocrystals to potentially treat osteolytic metastases |
title_fullStr | High affinity zoledronate-based metal complex nanocrystals to potentially treat osteolytic metastases |
title_full_unstemmed | High affinity zoledronate-based metal complex nanocrystals to potentially treat osteolytic metastases |
title_short | High affinity zoledronate-based metal complex nanocrystals to potentially treat osteolytic metastases |
title_sort | high affinity zoledronate-based metal complex nanocrystals to potentially treat osteolytic metastases |
topic | Chemistry |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8978309/ https://www.ncbi.nlm.nih.gov/pubmed/35445197 http://dx.doi.org/10.1039/d1ma01127h |
work_keys_str_mv | AT quinonesvelezgabriel highaffinityzoledronatebasedmetalcomplexnanocrystalstopotentiallytreatosteolyticmetastases AT carmonasarabialesly highaffinityzoledronatebasedmetalcomplexnanocrystalstopotentiallytreatosteolyticmetastases AT riveraraicesalondraa highaffinityzoledronatebasedmetalcomplexnanocrystalstopotentiallytreatosteolyticmetastases AT hutony highaffinityzoledronatebasedmetalcomplexnanocrystalstopotentiallytreatosteolyticmetastases AT petersonpegueroesthera highaffinityzoledronatebasedmetalcomplexnanocrystalstopotentiallytreatosteolyticmetastases AT lopezmejiasvilmali highaffinityzoledronatebasedmetalcomplexnanocrystalstopotentiallytreatosteolyticmetastases |